尤瑞克林对急性脑梗死合并2型糖尿病患者疗效分析

Analysis of clinical efficacy of urinary kallidinogenase in the treatment of acute cerebral infarct patients with type 2 diabetes mellitus

目的观察尤瑞克林对2型糖尿病合并急性脑梗死患者的临床疗效及安全性。方法合并2型糖尿病的急性脑梗死患者106例,随机分为治疗组(50例)和对照组(56例),对照组为对症治疗,治疗组在对症治疗基础上加尤瑞克林。采用美国国立卫生研究院脑卒中量表(NIHSS评分)、改良RankinScale(MRS评分)及日常生活能力量表(ADL评分)评定2组疗效,并随访半年评定Barthel指数(BI)分值。结果与对照组比较,治疗组NIHSS、MRS及ADL评分均明显改善(P<0.05)。随访6个月,尤瑞克林组Barthel指数较对照组高,差异有统计学意义(P<0.05)。结论尤瑞克林治疗合并2型糖尿病的急性脑梗死安全有效,改善预后。

Objective To observe the efficacy and safety of urinary kallidinogenase in the treatment of acute cerebral in- farct patients with type 2 diabetes meIlitus. Methods Totally 106 cases of combined type 2 diabetes patients with acute cerebral infarction were randomly divided into two groups. The placebo group （n= 56） accepted conventional treatment. The treatment group（n=50） accepted conventional therapy plus treatment with urinary kallidinogenase. The degree of clinical neurological deficit （NIHSS）, activity of daily living （ADL） and MRS scale before and after the treatment were assessed. Furthermore, the telephone follow-up Barthel index （BI） score was assessed after six months. Results Compared with control group, the NIH- SS, MRS, and ADL scores were significantly improved （P〈0.05）. The sexuality constituent ratios, age, plasma glucose of both groups were not different. Barthel index （BI） score of the treatment group was higher than control group after six months （P〈0.05）. Conclusion The treatment of acute cerebral infarction by urinary kallidinogenase is effective and safe, and it can improve the prognosis.